Loading…
Loading…
Just curious if you could give us more color on what a steady-state level of second-line starts look like.
can you comment on the trends you're seeing in the first line? Are you seeing a steady number of naive starts or an acceleration
Can you elaborate a bit more on sort of the half of the single patient prescribers in 2025 that have not written an additional script in Q1?
curious if you’ve had any discussions with the FDA regarding strain selection for 2027
how we should think about pricing for the COVID vaccine in the U.S. this year? And what your expectations are for net price
if you needed to or wanted to reduce R&D spend further, how much flexibility is there on the expense structure there for, say, further cuts in the 2026 time frame
On the clinical hold on Norovirus, can you give any more detail around sort of this, why one case of GBS prompted the clinical hold